180 related articles for article (PubMed ID: 34624079)
21. SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT.
Huo FC; Xie M; Zhu ZM; Zheng JN; Pei DS
Genomics; 2022 Jul; 114(4):110424. PubMed ID: 35798250
[TBL] [Abstract][Full Text] [Related]
22. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells.
Ji L; Tang Y; Pang X; Zhang Y
Med Sci Monit; 2019 Aug; 25():5823-5832. PubMed ID: 31379360
[TBL] [Abstract][Full Text] [Related]
23. Serine hydroxymethyltransferase 2 knockdown induces apoptosis in ccRCC by causing lysosomal membrane permeabilization via metabolic reprogramming.
Liu Z; Fan M; Hou J; Pan S; Xu Y; Zhang H; Liu C; Hao X; Li X; Wang H
Cell Death Dis; 2023 Feb; 14(2):144. PubMed ID: 36806313
[TBL] [Abstract][Full Text] [Related]
24. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis.
Wei Z; Song J; Wang G; Cui X; Zheng J; Tang Y; Chen X; Li J; Cui L; Liu CY; Yu W
Nat Commun; 2018 Oct; 9(1):4468. PubMed ID: 30367038
[TBL] [Abstract][Full Text] [Related]
25. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.
Bouska A; Bi C; Lone W; Zhang W; Kedwaii A; Heavican T; Lachel CM; Yu J; Ferro R; Eldorghamy N; Greiner TC; Vose J; Weisenburger DD; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; Siebert R; Miles RR; Dave S; Reddy A; Delabie J; Staudt LM; Song JY; McKeithan TW; Fu K; Green M; Chan WC; Iqbal J
Blood; 2017 Oct; 130(16):1819-1831. PubMed ID: 28801451
[TBL] [Abstract][Full Text] [Related]
26. [Expression of TCF3 in Burkitt's Lymphoma and Its Proliferative Effect and Prognostic Significance].
Dong LH; Huang JJ; Liu J; Gao X; DU JW; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1435-1439. PubMed ID: 36208246
[TBL] [Abstract][Full Text] [Related]
27. ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption.
Li X; Zhang K; Hu Y; Luo N
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894856
[TBL] [Abstract][Full Text] [Related]
28. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing.
Parsa S; Ortega-Molina A; Ying HY; Jiang M; Teater M; Wang J; Zhao C; Reznik E; Pasion JP; Kuo D; Mohan P; Wang S; Camarillo JM; Thomas PM; Jain N; Garcia-Bermudez J; Cho BK; Tam W; Kelleher NL; Socci N; Dogan A; De Stanchina E; Ciriello G; Green MR; Li S; Birsoy K; Melnick AM; Wendel HG
Nat Cancer; 2020; 1():653-664. PubMed ID: 33569544
[TBL] [Abstract][Full Text] [Related]
29. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of long non‑coding RNA ANRIL inhibits the proliferation and promotes the apoptosis of Burkitt lymphoma cells through the TGF‑β1 signaling pathway.
Mao S; Jin J; Li Z; Yang W
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33325535
[TBL] [Abstract][Full Text] [Related]
31. Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming.
Paiardini A; Tramonti A; Schirch D; Guiducci G; di Salvo ML; Fiascarelli A; Giorgi A; Maras B; Cutruzzolà F; Contestabile R
Biochim Biophys Acta; 2016 Nov; 1864(11):1506-17. PubMed ID: 27530298
[TBL] [Abstract][Full Text] [Related]
32. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
Pikman Y; Ocasio-Martinez N; Alexe G; Dimitrov B; Kitara S; Diehl FF; Robichaud AL; Conway AS; Ross L; Su A; Ling F; Qi J; Roti G; Lewis CA; Puissant A; Vander Heiden MG; Stegmaier K
Leukemia; 2022 Feb; 36(2):348-360. PubMed ID: 34341479
[TBL] [Abstract][Full Text] [Related]
33. Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.
Corso J; Pan KT; Walter R; Doebele C; Mohr S; Bohnenberger H; Ströbel P; Lenz C; Slabicki M; Hüllein J; Comoglio F; Rieger MA; Zenz T; Wienands J; Engelke M; Serve H; Urlaub H; Oellerich T
Proc Natl Acad Sci U S A; 2016 May; 113(20):5688-93. PubMed ID: 27155012
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition.
Chen L; Liu H; Ji Y; Ma Z; Shen K; Shangguan X; Qian H; Zhao Y; Pan CW; Xue W
Exp Cell Res; 2022 Jun; 415(2):113138. PubMed ID: 35398308
[TBL] [Abstract][Full Text] [Related]
35. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.
Kim D; Fiske BP; Birsoy K; Freinkman E; Kami K; Possemato RL; Chudnovsky Y; Pacold ME; Chen WW; Cantor JR; Shelton LM; Gui DY; Kwon M; Ramkissoon SH; Ligon KL; Kang SW; Snuderl M; Vander Heiden MG; Sabatini DM
Nature; 2015 Apr; 520(7547):363-7. PubMed ID: 25855294
[TBL] [Abstract][Full Text] [Related]
36. TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
Man J; Wang H; Qian X; Chen L; Ma Y; Qian M; Zhai X
Leuk Lymphoma; 2022 Oct; 63(10):2453-2460. PubMed ID: 35617527
[TBL] [Abstract][Full Text] [Related]
37. High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients.
Shi H; Fang X; Li Y; Zhang Y
Med Sci Monit; 2019 Oct; 25():7430-7438. PubMed ID: 31581160
[TBL] [Abstract][Full Text] [Related]
38. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
39. Serine hydroxymethyltransferase 2: a novel target for human cancer therapy.
Xie M; Pei DS
Invest New Drugs; 2021 Dec; 39(6):1671-1681. PubMed ID: 34215932
[TBL] [Abstract][Full Text] [Related]
40. Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-
Dekhne AS; Ning C; Nayeen MJ; Shah K; Kalpage H; Frühauf J; Wallace-Povirk A; O'Connor C; Hou Z; Kim S; Hüttemann M; Gangjee A; Matherly LH
Mol Pharmacol; 2020 Jan; 97(1):9-22. PubMed ID: 31707355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
